Tetracycline susceptibility of the ingested Lactobacillus acidophilus LaCH-5 and Bifidobacterium animalis subsp. lactis Bb-12 strains during antibiotic/probiotic intervention

International Journal of Antimicrobial Agents

Volumn 29, Issue 3, 2007, Pages 271-280

  Saarela, Maria ^a   Maukonen, Johanna ^a   von Wright, Atte ^b   Vilpponen Salmela, Terttu ^c   Patterson, Andrea J ^d   Scott, Karen P ^d   Hämynen, Heikki ^e   Mättö, Jaana ^a  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c Harjula Hospital   (Finland)

^d ROWETT RESEARCH INSTITUTE   (United Kingdom)

^e Oma Lääkäri Ltd   (Finland)

Author keywords

Bifidobacterium animalis; Doxycycline; Lactobacillus acidophilus; Susceptibility; tet(W); Tetracycline

Indexed keywords

DOXYCYCLINE; PROBIOTIC AGENT; TETRACYCLINE; TREVIS; UNCLASSIFIED DRUG;

ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; BIFIDOBACTERIACEAE; BIFIDOBACTERIUM ANIMALIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DRUG SAFETY; FECES ANALYSIS; FECES MICROFLORA; GASTROINTESTINAL TRACT; GENE TRANSFER; HUMAN; INGESTION; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; MICROBIAL DIVERSITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM; CASE-CONTROL STUDIES; DOXYCYCLINE; FECES; GASTROINTESTINAL TRACT; GENES, BACTERIAL; HUMANS; LACTOBACILLUS ACIDOPHILUS; PROBIOTICS; RESPIRATORY TRACT INFECTIONS; SAFETY; TETRACYCLINE RESISTANCE;

EID: 33847003691     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.09.020     Document Type: Article

References (36)

1. Food and Agriculture Organization of the United Nations/World Health Organization. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada: FAO/WHO; 2002.
2. Saavedra J.M. Probiotics plus antibiotics: regulating our bacterial environment. J Pediatr 135 (1999) 564-568
3. Sullivan A., and Nord C.E. Probiotics and gastrointestinal diseases. J Intern Med 257 (2005) 78-92
4. Armuzzi A., Cremonini F., Bartolozzi F., et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 15 (2001) 163-169
5. Armuzzi A., Cremonini F., Ojetti V., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 63 (2001) 1-7
6. Cremonini F., Di Caro S., Covino M., et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97 (2002) 2744-2749
7. Sheu B.-S., Wu J.J., Lo C.-Y., et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 16 (2002) 1669-1675
8. Tursi A., Brandimarte G., Giorgetti G.M., and Modeo M.E. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 10 (2004) CR662-CR666
9. Arvola T., Laiho K., Torkkeli S., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 104 (1999) e64
10. Vanderhoof J.A., Whitney D.B., Antonson D.L., Hanner T.L., Lupo J.V., and Young R.J. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 135 (1999) 564-568
11. Lidbeck A., Edlund C., Gustafsson J.-A., Kager L., and Nord C.E. Impact of Lactobacillus acidophilus on the normal intestinal microflora after administration of two antimicrobial agents. Infection 16 (1988) 329-336
12. Sullivan A., Barkholt L., and Nord C.E. Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. J Antimicrob Chemother 52 (2003) 308-311
13. Sullivan A., Johansson A., Svenungsson B., and Nord C.E. Effect of Lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. J Antimicrob Chemother 54 (2004) 791-797
14. Madden J.A.J., Plummer S.F., Tang J., et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol 5 (2005) 1091-1097
15. Jernberg C., Sullivan A., Edlund C., and Lansson J.K. Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl Environ Microbiol 71 (2005) 501-506
16. Plummer S.F., Garaiova I., Sarvotham T., et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 26 (2005) 69-74
17. Mättö J., Malinen E., Suihko M.-L., Alander M., Palva A., and Saarela M. Genetic heterogeneity and functional properties of intestinal bifidobacteria. J Appl Microbiol 97 (2004) 459-470
18. Atlas R.M. In: Parks L.C. (Ed). Handbook of microbiological media. 2nd ed. (1997), CRC Press, Boca Raton, FL 253
19. Alander M., Mättö J., Kneifel W., et al. Effect of galacto-oligosaccharide supplementation on human fecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int Dairy J 11 (2001) 817-825
20. Beerens H. Detection of bifidobacteria by using propionic acid as a selective agent. Appl Environ Microbiol 57 (1991) 2418-2419
21. Mättö J., Fondén R., Tolvanen T., et al. Intestinal survival and persistence of probiotic Lactobacillus and Bifidobacterium strains administered in triple-strain yoghurt. Int Dairy J 16 (2006) 1174-1180
22. Mättö J., Maunuksela L., Kajander K., et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43 (2005) 213-222
23. Klare I., Konstabel C., Müller-Bertling S., et al. Evaluation of new broth media for microdilution antibiotic susceptibility testing of lactobacilli, pediococci, lactococci, and bifidobacteria. Appl Environ Microbiol 71 (2005) 8982-8986
24. Mättö J., Suihko M.-L., and Saarela M. Comparison of three test media for the antimicrobial susceptibility testing of bifidobacteria with the Etest method. Int J Antimicrob Agents 28 (2006) 42-48
25. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
26. Barbosa T.M., Scott K.P., and Flint H.J. Evidence for recent intergeneric transfer of a new tetracycline resistance gene, tet(W), isolated from Butyrivibrio fibrisolvens, and the occurrence of tet(O) in ruminal bacteria. Environ Microbiol 1 (1999) 53-64
27. Scott K., Melville C.M., Barbosa T.M., and Flint H.J. Occurrence of the new tetracycline resistance gene tet(W) in bacteria from the human gut. Antimicrob Agents Chemother 44 (2000) 775-777
28. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 6th ed. M11-A6. Wayne, PA: NCCLS; 2004.
29. Wullt M., Johansson Hagslätt M.-L., and Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35 (2003) 365-367
30. Moubareck C., Gavini F., Vaugien L., Butel M.J., and Doucet-Populaire F. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother 55 (2005) 38-44
31. Delgado S., Flórez A.B., and Mayo B. Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract. Curr Microbiol 50 (2005) 202-207
32. Danielsen M., and Wind A. Susceptibility of Lactobacillus spp. to antimicrobial agents. Int J Food Microbiol 82 (2003) 1-11
33. Tankovic J., Leclerco R., and Duval J. Antimicrobial susceptibility of Pediococcus spp. and genetic basis of macrolide resistance in Pediococcus acidilactici HM3020. Antimicrob Agents Chemother 37 (1993) 789-792
34. Donskey C.J., Hujer A.M., Das S.M., Pultz N.J., Bonomo R.A., and Rice L.B. Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Methods 54 (2003) 249-256
35. De La Cochetiere M.F., Durand T., Lepage P., Bourreille A., Galmiche J.P., and Doré J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 43 (2005) 5588-5592
36. Masco L., Van Hoorde K., De Brandt E., Swings J., and Huys G. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother 58 (2006) 85-94